Compare SNA & RVMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SNA | RVMD |
|---|---|---|
| Founded | 1920 | 2014 |
| Country | United States | United States |
| Employees | N/A | 883 |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 19.1B | 19.2B |
| IPO Year | 1994 | N/A |
| Metric | SNA | RVMD |
|---|---|---|
| Price | $376.63 | $141.25 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 5 | 19 |
| Target Price | ★ $376.80 | $140.84 |
| AVG Volume (30 Days) | 366.7K | ★ 3.8M |
| Earning Date | 04-23-2026 | 05-07-2026 |
| Dividend Yield | ★ 2.58% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 4.69 | N/A |
| Revenue | ★ $5,156,100,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.66 | $533.02 |
| P/E Ratio | $80.17 | ★ N/A |
| Revenue Growth | ★ 0.93 | N/A |
| 52 Week Low | $304.90 | $34.00 |
| 52 Week High | $400.88 | $155.70 |
| Indicator | SNA | RVMD |
|---|---|---|
| Relative Strength Index (RSI) | 50.97 | 63.06 |
| Support Level | $358.04 | $93.39 |
| Resistance Level | $389.02 | $155.70 |
| Average True Range (ATR) | 10.29 | 7.53 |
| MACD | 0.01 | -0.06 |
| Stochastic Oscillator | 36.35 | 75.84 |
Snap-on is a manufacturer of premium tools, equipment, and diagnostics for professional technicians, primarily involved in the repair of passenger cars but having expanded into other industrial applications. The company's legacy business is selling hand tools through franchisee-operated mobile vans to technicians who purchase the tools at their own expense. The company also operates a commercial and industrial business that is focused on repair facilities serving other industries. The third segment, repair systems and information, targets auto OEMs and large dealerships more directly and also offers substantial diagnostic solutions to aid repairs. The company's finance arm provides financing to franchisees to run their operations, as well as underwriting end customer purchases.
Revolution Medicines Inc is a clinical-stage precision oncology company developing novel targeted therapies for RAS-addicted cancers. The Company possesses structure-based drug discovery capabilities built upon chemical biology and cancer pharmacology know-how and proprietary technologies that enable the creation of small molecules tailored to unconventional binding sites. Its research and development pipeline comprises inhibitors that bind directly to RAS variants (RAS(ON) Inhibitors), designed to be used as monotherapy, in combination with other RAS(ON) Inhibitors and/or other therapeutic agents.